Eli Lilly
Trade Eli Lilly 24 hours a day, five days a week on Robinhood.
Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.About LLY
Eli Lilly & Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. The firm's products consist of diabetes, oncology, immunology, neuroscience, and other products and therapies.
LLY Key Statistics
Stock Snapshot
The current Eli Lilly(LLY) stock price is $1,019.00, with a market capitalization of 963.35B. The stock trades at a price-to-earnings (P/E) ratio of 48.58 and offers a dividend yield of 61.1%.
As of 2025-12-11, Eli Lilly(LLY) stock has fluctuated between $987.00 and $1,031.56. The current price stands at $1,019.00, placing the stock +3.2% above today's low and -1.2% off the high.
Eli Lilly(LLY) shares are trading with a volume of 2.83M, against a daily average of 3.06M.
In the last year, Eli Lilly(LLY) shares hit a 52-week high of $1,111.99 and a 52-week low of $623.78.
In the last year, Eli Lilly(LLY) shares hit a 52-week high of $1,111.99 and a 52-week low of $623.78.
LLY News
Eli Lilly on Thursday said its next-generation obesity drug delivered what appears to be the highest weight loss yet in a late-stage trial while reducing knee a...
Pharmaceutical giant Eli Lilly & Co. (LLY) has announced that its newest obesity drug called Retatrutide delivered what appears to be the highest weight loss ye...
Biotech and Pharma Eli Lilly’s Latest Obesity Drug Delivers Strong Results. It Might Work Too Well. In this article LLY ZBH Eli Lilly is trying to maintain its...
Analyst ratings
74%
of 31 ratingsMore LLY News
Eli Lilly and Co (NYSE:LLY) on Thursday shared topline results from the Phase 3 TRIUMPH-4 trial evaluating the two highest investigational doses of retatrutide....
Morgan Stanley analyst Terence Flynn says Eli Lilly’s (LLY) retatrutide delivered what the firm views as “a competitive efficacy profile” in the first Phase 3 t...
Eli Lilly is developing a new generation of obesity drugs, including retatrutide, to increase effectiveness and treat a wider range of conditions. Carolyn Fong...
Eli Lilly’s “triple g” drug helped patients lose about 28.7% of their body weight while also reducing pain associated with knee osteoarthritis in a Phase 3 tria...
Eli Lilly’s experimental weight-loss drug retatrutide resulted in significant weight loss and reduced knee pain in a phase three trial involving patients with o...
Eli Lilly (LLY) announced topline results from the Phase 3 TRIUMPH-4 clinical trial evaluating the safety and efficacy of the two highest investigational doses...
Eli Lilly and Company recently announced plans to invest more than US$6.00 billion in a new Huntsville, Alabama manufacturing site to produce small-molecule and...
